Figure 3

Quantitative proteomic analysis reveals the pathways enriched for the significantly changed proteins that mediate the inhibition effect of zedoarondiol on proliferation. (a) HBSMCs were treated as in Fig. 1d. Multivariate analysis by means of principal component analysis (PCA) of all group specific protein concentration levels allowed clear separation of the different samples according to their treatment group. (b) Volcano plot displays the distribution of proteins (P < 0.05, log₂(fold change) > log₂(1.5)) quantified in proteomic study. (c) GO pathway enrichment analysis (BP: biological process) based on significantly changed proteins. Representative pathways are shown. (d) Heatmap shows the normalized abundances of significantly changed proteins (affect cell proliferation) (P < 0.05, log₂ (fold change) > log₂ (1.5)) in Zed-treated cells compared with the PDGF-BB-stimulated cells.